Wednesday, September 28, 2011 (Last Updated: 09/29/2011)
WEDNESDAY, Sept. 28 (HealthDay News) -- DNA repair capacity (DRC) in peripheral lymphocytes is a significant, independent predictor of survival for patients with non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Li-E Wang, M.D., from The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues investigated whether DRC in peripheral lymphocytes predicted survival in 591 patients with NSCLC who received first-line platinum-based chemotherapy. Blood samples collected prior to chemotherapy initiation were used to determine DRC in cultured T lymphocytes using the host-cell reactivation assay.
The investigators found that DRC in peripheral lymphocytes was inversely associated with patient survival. Patients in the highest tertile of DRC exhibited significantly worse overall and three-year survival compared to those in the lowest DRC tertile (adjusted hazard ratio, 1.33 and 1.35, respectively). This trend was more prominent in patients with adenocarcinoma, early-stage tumors, or squamous cell carcinoma.
"It is promising to use DRC in peripheral lymphocytes as a prognostic factor to guide tailored individual therapeutics for patients with NSCLC," the authors write.
Two of the study authors disclosed financial relationships with AstraZeneca.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.